Related Experiment Video
Updated: Jun 28, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Impending flop for brand antiretrovirals in the emerging markets?
Dionisio Daniele1, Messeri Daniela
1Access to Drugs: International Policies--Italian Network for International Fight against AIDS, Italian Society for Infectious and Tropical Diseases, Division of Infectious Diseases, Pistoia Hospital, Pistoia, Italy. d.dionisio@usl3.toscana.it
Abstract:
Forecasts from Country choices, South-South partnerships and Clinton Foundation-UNITAID coalition show that present policies for brand ARVs are at the risk of flop in emerging South markets such as India, China, Thailand and Brazil.The dynamics explored in this article highlight the risks the originator companies are running in the emerging markets, along with their interest in direct agreements with the generic industry for the manufacturing and marketing of ARVs.Resulting information here would suggest the brand enterprises:To look for fast registration of their ARVs by regulatory authorities in all countries enlisted for differential pricing.To secure all formulations differentiated prices.To align with the Clinton-UNITAID prices for the corresponding generics.To pursue flexible negotiations with the generic companies to secure both counterparts long-term advantages.
Related Concept Videos
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Retroviruses
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Subviral Agents

